3rd Annual Oncology Biomarkers Congress, 14th & 15th October 2013, Manchester
This event provides invaluable insight into the progression of oncology biomarker research from initial discovery through to the development of fully validated companion diagnostics.
Too often, the diagnosis of cancer happens in the late stages of the disease; molecular biomarkers provide a promising prospect for the detection of early stage cancer. On day one, our industry leaders will discuss the latest screening methods and the use of oncology imaging biomarkers in clinical trials. Our internationally renowned speakers will also assess the latest profiling technologies and their impact on biomarker development.
On day two, the discussions will focus on the role of tumour banks in personalised medicine, strategies for the co-development of drug and diagnostics and methods of assay development for the validation of companion diagnostics. Our experts will also discuss the importance of partnering relationships in enhancing the safety and efficacy of personalised medicine.
For more information please email firstname.lastname@example.org or visit http://www.oncologybiomarkers-congress.com/